Article

Studying the brain-gut axis with pharmacological imaging.

Center for Neurobiology of Stress, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095-6949, USA.
Annals of the New York Academy of Sciences (Impact Factor: 4.31). 12/2008; 1144:256-64. DOI: 10.1196/annals.1418.025
Source: PubMed

ABSTRACT Pharmacological imaging provides great potential both for evaluating the efficacy of new candidate compounds in the treatment of gastrointestinal symptom-based disorders, and for furthering our understanding of the underlying pathophysiology of such disorders. By combining evaluation of symptoms, behavior, and brain responses to relevant stimuli, use of neuroimaging is able to move the study of brain-gut disorders away from more subjective outcomes and emphasize the underlying neural networks involved in symptom generation and treatment. This chapter reviews the state of the art in pharmacological imaging studies, both in human subjects and in animal models of brain-gut interactions.

Download full-text

Full-text

Available from: Emeran A Mayer, Mar 11, 2014
0 Followers
 · 
102 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: The majority of functional gastrointestinal disorders are characterised by recurrent abdominal pain, with stress playing an important role in first onset and exacerbation of existing symptoms. These disorders are currently defined by symptom criteria, while their pathophysiology remains controversial and incompletely understood. Modeling these disorders in humans and animals has been difficult. While some of the models have adequate face and construct validity, the predictive validity of most of the models has been disappointing, which has put into question the traditional modeling approach. Similar problems have been encountered in drug development for pain and psychiatric disorders. New approaches have been proposed in the form of reverse translation, which include better characterisation of biological intermediate phenotypes in human disease which can be modeled in humans and in animals. Continuation of the current approach focusing on complex clinical phenotypes is likely to be ineffective for the development of novel and effect treatments.
    Digestive Diseases 01/2009; 27 Suppl 1:55-67. DOI:10.1159/000268122
  • [Show abstract] [Hide abstract]
    ABSTRACT: Evaluation of: Silk DBA, Davis A, Vulevic J, Tzortzis G, Gibson GR. Clinical trial: the effects of a trans-galactooligosaccharide on faecal microbiota and symptoms in irritable bowel syndrome. Aliment. Pharmacol. Ther. 29, 508-518 (2009). While a variety of probiotic preparations have been quite extensively studied in the short-term treatment of irritable bowel syndrome (IBS), little is known regarding the efficacy of prebiotics - the nondigestible but fermentable foods that promote the growth of one or a number of species of beneficial commensal flora in the human colon - in IBS. In this study, a specially designed prebiotic, a trans-galactooligosaccharide, was studied in two doses, 3.5 and 7 g, in a single-blind, randomized, placebo-controlled trial of 4-weeks duration in Rome II-positive IBS patients. The researchers found that the prebiotic altered the fecal flora, increasing the numbers of Bifidobacteria in a dose-dependent manner and also improved, but in a less predictable manner, individual IBS symptoms, such as flatulence and bloating, as well as impacting on a composite score of the subjects' global assessment of relief and quality of life. This study indicates that prebiotics, either on their own or in combination with a probiotic, deserve further study in IBS.
    Expert review of gastroenterology & hepatology 10/2009; 3(5):487-92. DOI:10.1586/egh.09.46
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Clinical and preclinical evidence suggests anxiolytic-like efficacy of pregabalin (PGB, Lyrica). However, its mechanism of action remains under investigation. The current study applied [(14)C]-iodoantipyrine cerebral blood flow (CBF) mapping to examine the effect of PGB on neural substrates underlying unconditioned fear in a rat model of footshock-induced fear. Regional CBF (rCBF) was analyzed by statistical parametric mapping. Functional connectivity and graph theoretical analysis were used to investigate how footshock and PGB affect brain activation at the network level. Pregabalin significantly attenuated footshock-induced ultrasonic vocalization, but showed no significant effect on freezing behavior. Footshock compared to no-shock controls elicited significant increases in rCBF in limbic/paralimbic regions implicated in the processing of unconditioned fear and ultrasonic vocalization, including the amygdala, hypothalamus, lateral septum, dorsal periaqueductal gray, the anterior insular (aINS) and medial prefrontal cortex (mPFC). The activation pattern was similar in vehicle- and PGB-treated subjects, with PGB significantly attenuating activation in the amygdala, hypothalamus, and aINS. The vehicle/no-shock group showed strong, positive intra-structural correlations within the cortex, hypothalamus, amygdala, thalamus, and brainstem. The cortex was negatively correlated with the hypothalamus and brainstem. Footshock reduced the total number of significant correlations, but induced greater intra-cortical connectivity of the aINS and mPFC, and new positive correlations between the hypothalamus and amygdala. In no-shock controls, PGB significantly reduced the positive intra-structural correlations within the cortex and amygdala, as well as the negative cortico-subcortical correlations. Following footshocks, PGB disrupted both the network recruitment of aINS and mPFC, and the positive hypothalamic-amygdaloid correlations. Our findings suggest that PGB may exert anxiolytic effect by attenuating cortico-cortical and cortico-subcortical communication and inhibiting network recruitment of the aINS, mPFC, amygdala, and hypothalamus following a fear-inducing stimulus. Functional brain mapping in rodents may provide new endpoints for preclinical evaluation of anxiolytic drug candidates with potentially improved translational power compared to behavioral measurements alone.
    NeuroImage 12/2011; 59(4):4168-88. DOI:10.1016/j.neuroimage.2011.11.047